SlideShare a Scribd company logo
1 of 9
Homework Help
https://www.homeworkping.com/
Research Paper help
https://www.homeworkping.com/
Online Tutoring
https://www.homeworkping.com/
UKRIDA
MAGISTER MANAGEMENT PROGRAM
PERIODE 2010
Class: Creative Marketing
By Prof Dr…
Analysis on the Case 2-4
Johnson & Johnson
Prepared By:
1. Darwin Lesmana NIM : 01-2010-12
2. ….
3. ….
4. …
5. …
6. …
7. …
1. Introduction:
 Johnson & Johnson (“J&J”) is one of the largest enterprises in the world. The
Company has established for 117 years, made up with 204 different businesses
organized into three divisions:
a. Drugs (Pharmaceutical)
b. Medical Devices & Diagnostic
c. Consumer Products.
 The Pharmaceutical division is the major contributor to the Company’s Growth,
they accounted for almost half of the Company’s Sales and contribute 61% of the
previous year operating profit. The consumer products Band Aid and Baby
Powder is also well known to consumer.
 The Company also well known for the development of Innovative Products,
aggressive selling, favorable prices and an unusual move of advertisement,
example:
- In 1991, they launch Procrit (for treating Anemia in Chemotheraphy) where
J&J spend millions to educate physician and also advertisement on TV. This
is an unusual common practice for Cancer Drug to be advertised on TV,
however they succeed with the proven that Procrit is now the best selling drug
of J&J.
 J&J is famed for giving for delivering at least 10% earnings growth year in and
year out going back nearly two decades. In the first quarter, it reported 13% rise.
The Stock Price has increased from less than $ 3 in the mid 1980 to almost 20
times that now. Although the Standard and Poors 500 Stock index has fallen
28,1% but J&J stock increased 19,4%. In 2002, J&J earned $ 6,8 billion
compared with $ 5.9 billion the previous year (15% growth)
 J&J is fulfilled with great employees, however one of the great employees was
William C Weldons, who was onetime a drug salesman and now becoming the
leader of the Health Care Division. He is famed for the ability to convince, cajole
and sometimes just sweet talk colleagues into seeing things his way. One of the
most succesful story of Weldons ability in convincing people was when he
succeeded in persuading the Chief Pharmaceutical “ Dr Per A Peterson” to stay
for J&J, although the Doctor has decide for leaving the Company.
2. Important Highlights
 Maintaining the growth records to keep sustainably increase was one of the
Company’s problems. To keep up, the Company must make a new $ 4 billion
business every year. Meanwhile there were some difficulties which the
Company’s facing such as:
- Procrit sales were nearly flat in the 1st quarter due to the new rival, and the
news has impacting on the Company’s stock which decrease 3% in one day.
- Although the new drug coated stent has been held up at the Food and Drug
Administration and approval seems highly likely but if the devices does not
get the OK , it would be one big problem for J&J.
 J&J style in acquisitions to continue growing has also created another problem.
The Company has bought 52 business for over $ 30 billion over the past decade,
10-15% of top line growth was due to investment. Finding and acquisition that is
fit with the Company’s business and make contribution becomes increasingy
difficult.
 J&J is one big Company with many subsidiaries, where each of the subsidiaries
run their own Company independently. Each of the Subsidiaries set their own
strategies, their own finance and human resources departments. This is creating
a relatively high overhead cost.
 Weldons as one the leader in J&J has believe that the important breakthrough in
the 21st Century medicine is the ability to apply scientific advances in one
discipline to another, such as:
- Sutures are coated with drugs to prevent infections.
- Defibrillators may be linked to computer that alerts doctors when patient have
abnormal heart diseases.
The Company should combine between Drugs, Devices & Diagnostic. By
implementing that, it has boost the Development and Research Budget by more
than 10%, and it has employed 9.300 scientist in 40 labs around the world.
 In order to achieve the 21st Century breakthrough, J&J’s independent business
unit (Subsidiaries) must work together. Therefore Weldon has created a new
system to foster better communication and more frequent collaboration among
J&J disparate operations.
 J&J has been inching to that with the new drugs coated stent which could
revolutionize the field of cardiology. It has grew out of a discussion in the mid
90’s between Drug researcher and one in J&J stent business. This kind of
example is what the Company’s need in order to make the independent business
unit (Subsidiaries) work together.
 Inline the breakthrough, Weldons personifies the Company’s Ethos such as:
- Although becoming the first Executives to go casual in 1990, but he is a
compulsively competitive. One of the famous quotation was: “ It’s not fun to
be second”.
- Weldon was also became famous for setting near impossible goals for his
people.
- His is turning up the Company’s with the cooperation between his different
units to have meeting quarterly for the past five years to share information.
- Creating new breakthrough such as creating committee comprised of R&D
executives and senior managers instead of scientist for some fixing some
failure.
 Although the breakthrough by Weldon wont yield results for years, however there
was some evidence that the new collaboration is working, such as:
- J&J Pharmaceutical operation working the Companys’ drug delivery operation
Alza.
- New diagnostic unit is working with data generated by drug researcher.
- In 2002, J&J rolled out the new Band Aid Brand, which formerly used by
hospital, now sold through the public.
- Changes in prescription antifungal treatment Nizoral into a dandruff
Shampoo.
These changes has increase the Operating Margins for the Consumer Business
from 13,8% in 2000 to 18,7% in 2002.
 Facts about Weldon:
- Weldon spent much of his time on the road travelling to meet surgeons and
hospital executives.
- Weldon often set more ambitious goals than the headquarters.
- He doesn’t like to be disappointed.
- He is an intimidator and a dominator
- Weldon’s background was not from a wealthy educated family. His father was
a stagehand on Broadway, while his mother was a seamstress worked for the
ballet and theater costumes.
- Weldon was grew up in one of the less prosperous neighborhood.
- While in college, he has begin to work as a mover on the weekends and
public holidays.
- He’s first and only interview for work as at J&J and started his career as a
salesman at the Mc Neil Pharmaceutical units.
 At this point, most of J&J’s important drugs as under threat from competitors,
such as:
- Procrit (Company’s biggest selling product) has been threat by Aranesp
(product from Amgen Inc) and also side problem from European version
called Eprex which resulting Procrit sales may actually decline 2% in 2003.
- $1.3 billions Rheumatoid Arthritis drug Remicade faces competing products
from Amgen and Abbott Labs.
 With the J&J blockbusters slowing, Weldon expect his successor to do
something dramatic, like what he did two years ago when he completed J&J
biggest acquisition ever by buying the drug delivery player Alza corp for $13.2
Billion. Reason for the acquisition was Alza’s Technology could help J&J devise
safer and more effective formulations of exisiting drugs. But buying growth would
be difficult these days. Nearly every pharmaceutical company is looking for deal
with J&J, but finding the right one would be a difficult problems.
 Now the drugs business is taken care by the new boss Christine A Poon who
was recruited by Waldens from Bristol Myers Squibb Co. But Weldons still jumps
in every now and then. Such as when the Senior Executives was hammering out
details of $ 2.4 Billions acquisitions of Scios Inc, Walden came and supporting
Poons, due to it was her first acquisitions. But Waldons also have to be carefull
not to cross the line between supporting his executives and encroaching on their
territory.
3. Implication to the Market Driven Strategies:
a. Becoming Market- Orientation
J&J has become the Market Orientation which can be proven by the facts
about:
- They keep on focusing on their core business in Drug, Medicine Devices
and Consumer Products and keep on continuing on research for what the
market demands and creating innovative products. Example new drug
coated stent called Cypher. Stent is used to prop open arteries after
angioplasty, Cypher is coated with a drug that prevents those arteries from
re-clogging.
- Almost all consumer known the products of Band Aid and Baby powder
which quality was consistently control, showing that J&J brands has been
the market orientation.
b. Determining Distinctive Capabilities
Distinctive Capabilities that J&J have was:
- J&J have one of the Best Human Resources Assets which was Mr William
C Weldon who has super brilliant ideas which changes the ethos of J&J
work attitude, by creating an cooperation between Drugs, Medical Services
and Diagnostics.
- With the Company’s wealth over 2 decades of 10% sustain growth, they
have precious assets in developing new products with employing over
9.300 scientist in 40 labs around the world.
- Also inline with the Company’s wealth, they have the potential money in
acquisition of some company’s which core business will support the
development of J&J, such as the purchased of Technology Company Alza.
c. Customers Value/Capabilities Match
Creating value for customers:
- Hospital purchase products from J&J due to the favourable prices that
J&J given for the whole package, giving the best product with the best
price to the customers.
- The Producs Cypher giving value to the Stent with coating it with drugs
which prevents those arteries from reclogging, which was giving value to
the patients.
- The Company’s sustainable growth which made the stock growth almost
20 times from less than $ 3, which giving values and benefit for the
stockholders.
d. Achieving Superior Performance
J&J has achieve Superior Performance such as:
- In the first quarter, it reported 13% rise. The Stock Price has increased
from less than $ 3 in the mid 1980 to almost 20 times that now. Although
the Standard and Poors 500 Stock index has fallen 28,1% but J&J stock
increased 19,4%. In 2002, J&J earned $ 6,8 billion compared with $ 5.9
billion the previous year (15% growth).
However although it has achieve the superior performance, there were some
obstacle:
- Maintaining the growth records to keep sustainably increase was one of
the Company’s problems. To keep up, the Company must make a new $
4 billion business every year.
- Finding and acquisition that is fit with the Company’s business and make
contribution becomes increasingy difficult.
- J&J is one big Company with many subsidiaries, where each of the
subsidiaries run their own Company independently. Each of the
Subsidiaries set their own strategies, their own finance and human
resources departments. This is creating a relatively high overhead cost.
4. Conclusion:
In order for the Companys to keep continuing:
a. In order to achieve the 21st Century breakthrough, J&J’s independent
business unit (Subsidiaries) must work together. This program must work in
order to makes more innovative products.
b. With the collaboration, they should make some merger of some company’s in
order to reduce the High Cost of Overhead, Finance and Human Resources
Department.
c. Be More selective and more prudent in acquisition, must ensure that the
acquisition is really2 inline with the Company’s core business.
Homework Help
https://www.homeworkping.com/
Math homework help
https://www.homeworkping.com/
Research Paper help
https://www.homeworkping.com/
Algebra Help
https://www.homeworkping.com/
Calculus Help
https://www.homeworkping.com/
Accounting help
https://www.homeworkping.com/
Paper Help
https://www.homeworkping.com/
Writing Help
https://www.homeworkping.com/
Online Tutor
https://www.homeworkping.com/
Online Tutoring
https://www.homeworkping.com/

More Related Content

What's hot

Novartis master minds 2009 final
Novartis master minds 2009 finalNovartis master minds 2009 final
Novartis master minds 2009 finalJames Ward
 
Emerging Trends In Pharma - HR Update
Emerging Trends In Pharma - HR UpdateEmerging Trends In Pharma - HR Update
Emerging Trends In Pharma - HR UpdateShibumi2009
 
BioEntrepreneurship: Life Science Business Models
BioEntrepreneurship: Life Science Business ModelsBioEntrepreneurship: Life Science Business Models
BioEntrepreneurship: Life Science Business ModelsMaRS Discovery District
 
01 150613 Pharma CV HSNYSVallespirGenStd
01 150613 Pharma CV HSNYSVallespirGenStd01 150613 Pharma CV HSNYSVallespirGenStd
01 150613 Pharma CV HSNYSVallespirGenStdSteve Vallespir
 
Pfizer Strategic Analysis
Pfizer Strategic AnalysisPfizer Strategic Analysis
Pfizer Strategic AnalysisPharm Net
 
Synthon, The Value Chain of a specialty pharmaceutical company
Synthon, The Value Chain of a specialty pharmaceutical companySynthon, The Value Chain of a specialty pharmaceutical company
Synthon, The Value Chain of a specialty pharmaceutical companyHealth Valley
 
R&D leadership in crisis: rebuilding innovation through people
R&D leadership in crisis: rebuilding innovation through peopleR&D leadership in crisis: rebuilding innovation through people
R&D leadership in crisis: rebuilding innovation through peopleRung Jaismut
 
Novartis AG: Science-Based Business
Novartis AG: Science-Based BusinessNovartis AG: Science-Based Business
Novartis AG: Science-Based BusinessKaran Jaidka
 
Novartis cr-performance-report-2015
Novartis cr-performance-report-2015Novartis cr-performance-report-2015
Novartis cr-performance-report-2015Ethos Media S.A.
 
Dendreon Presentation
Dendreon PresentationDendreon Presentation
Dendreon Presentationafa4
 
Market access conference NAPM
Market access conference NAPMMarket access conference NAPM
Market access conference NAPMnapmSA
 
Frost & Sullivan - Initiation of Coverage - Oramed Pharmaceuticals
Frost & Sullivan - Initiation of Coverage - Oramed Pharmaceuticals Frost & Sullivan - Initiation of Coverage - Oramed Pharmaceuticals
Frost & Sullivan - Initiation of Coverage - Oramed Pharmaceuticals Daniel Grunstein
 
Competitive Analysis in Pharmaceutical Industry
Competitive Analysis in Pharmaceutical IndustryCompetitive Analysis in Pharmaceutical Industry
Competitive Analysis in Pharmaceutical IndustryYee Jie NG
 
Business Plan on a Bio-Tech product
Business Plan on a Bio-Tech productBusiness Plan on a Bio-Tech product
Business Plan on a Bio-Tech productTarkeshwar Singh
 
Emerging Pharma Business & Operational Models
Emerging Pharma Business & Operational ModelsEmerging Pharma Business & Operational Models
Emerging Pharma Business & Operational ModelsSurya Chitra,PhD MBA
 
About Pfizer Company
About Pfizer CompanyAbout Pfizer Company
About Pfizer Companyindira 7
 
Pfizer-Strategic Management Case
Pfizer-Strategic Management CasePfizer-Strategic Management Case
Pfizer-Strategic Management CaseSanjaya Sanjaya
 

What's hot (20)

Novartis master minds 2009 final
Novartis master minds 2009 finalNovartis master minds 2009 final
Novartis master minds 2009 final
 
Emerging Trends In Pharma - HR Update
Emerging Trends In Pharma - HR UpdateEmerging Trends In Pharma - HR Update
Emerging Trends In Pharma - HR Update
 
BioEntrepreneurship: Life Science Business Models
BioEntrepreneurship: Life Science Business ModelsBioEntrepreneurship: Life Science Business Models
BioEntrepreneurship: Life Science Business Models
 
01 150613 Pharma CV HSNYSVallespirGenStd
01 150613 Pharma CV HSNYSVallespirGenStd01 150613 Pharma CV HSNYSVallespirGenStd
01 150613 Pharma CV HSNYSVallespirGenStd
 
Pfizer Strategic Analysis
Pfizer Strategic AnalysisPfizer Strategic Analysis
Pfizer Strategic Analysis
 
Synthon, The Value Chain of a specialty pharmaceutical company
Synthon, The Value Chain of a specialty pharmaceutical companySynthon, The Value Chain of a specialty pharmaceutical company
Synthon, The Value Chain of a specialty pharmaceutical company
 
R&D leadership in crisis: rebuilding innovation through people
R&D leadership in crisis: rebuilding innovation through peopleR&D leadership in crisis: rebuilding innovation through people
R&D leadership in crisis: rebuilding innovation through people
 
Novartis AG: Science-Based Business
Novartis AG: Science-Based BusinessNovartis AG: Science-Based Business
Novartis AG: Science-Based Business
 
Novartis cr-performance-report-2015
Novartis cr-performance-report-2015Novartis cr-performance-report-2015
Novartis cr-performance-report-2015
 
NAPM Review Dec 2015
NAPM Review Dec 2015NAPM Review Dec 2015
NAPM Review Dec 2015
 
Dendreon Presentation
Dendreon PresentationDendreon Presentation
Dendreon Presentation
 
Pfizer Inc
Pfizer IncPfizer Inc
Pfizer Inc
 
Market access conference NAPM
Market access conference NAPMMarket access conference NAPM
Market access conference NAPM
 
Frost & Sullivan - Initiation of Coverage - Oramed Pharmaceuticals
Frost & Sullivan - Initiation of Coverage - Oramed Pharmaceuticals Frost & Sullivan - Initiation of Coverage - Oramed Pharmaceuticals
Frost & Sullivan - Initiation of Coverage - Oramed Pharmaceuticals
 
Competitive Analysis in Pharmaceutical Industry
Competitive Analysis in Pharmaceutical IndustryCompetitive Analysis in Pharmaceutical Industry
Competitive Analysis in Pharmaceutical Industry
 
Business Plan on a Bio-Tech product
Business Plan on a Bio-Tech productBusiness Plan on a Bio-Tech product
Business Plan on a Bio-Tech product
 
mba 599- pfizer
mba 599- pfizermba 599- pfizer
mba 599- pfizer
 
Emerging Pharma Business & Operational Models
Emerging Pharma Business & Operational ModelsEmerging Pharma Business & Operational Models
Emerging Pharma Business & Operational Models
 
About Pfizer Company
About Pfizer CompanyAbout Pfizer Company
About Pfizer Company
 
Pfizer-Strategic Management Case
Pfizer-Strategic Management CasePfizer-Strategic Management Case
Pfizer-Strategic Management Case
 

Similar to Johnson & Johnson's Success Through Innovation and Collaboration

CASE TO BE ANALYZED LISTED BELOW THE ASSIGNMENTCOMPAN
CASE TO BE ANALYZED LISTED BELOW THE ASSIGNMENTCOMPANCASE TO BE ANALYZED LISTED BELOW THE ASSIGNMENTCOMPAN
CASE TO BE ANALYZED LISTED BELOW THE ASSIGNMENTCOMPANogglili
 
Newtech advant-business-plan9
Newtech advant-business-plan9Newtech advant-business-plan9
Newtech advant-business-plan9Yousaf Khan
 
20071012 ow _beyond_blockbuster
20071012 ow _beyond_blockbuster20071012 ow _beyond_blockbuster
20071012 ow _beyond_blockbusterKadir Kumbo
 
johnson n johnson
johnson n johnsonjohnson n johnson
johnson n johnsonanand karki
 
Dendreon Strategic Analysis
Dendreon Strategic AnalysisDendreon Strategic Analysis
Dendreon Strategic Analysisafa4
 
Biotechnology 1
Biotechnology 1Biotechnology 1
Biotechnology 1sokraturk
 
Johnson & johnson Business Strategy
Johnson & johnson Business StrategyJohnson & johnson Business Strategy
Johnson & johnson Business StrategyPriyanka Gujral
 
Big pharma-uncertain-future
Big pharma-uncertain-futureBig pharma-uncertain-future
Big pharma-uncertain-futurefrank45
 
johnsonjohnsonbusinessstrategy-140417033017-phpapp02.pdf
johnsonjohnsonbusinessstrategy-140417033017-phpapp02.pdfjohnsonjohnsonbusinessstrategy-140417033017-phpapp02.pdf
johnsonjohnsonbusinessstrategy-140417033017-phpapp02.pdfShivangiSinha48
 
The future of the pharma industry 11.07
The future of the pharma industry 11.07The future of the pharma industry 11.07
The future of the pharma industry 11.07Maria Zaritskaya
 

Similar to Johnson & Johnson's Success Through Innovation and Collaboration (20)

CASE TO BE ANALYZED LISTED BELOW THE ASSIGNMENTCOMPAN
CASE TO BE ANALYZED LISTED BELOW THE ASSIGNMENTCOMPANCASE TO BE ANALYZED LISTED BELOW THE ASSIGNMENTCOMPAN
CASE TO BE ANALYZED LISTED BELOW THE ASSIGNMENTCOMPAN
 
The 10 most eminent leaders in pharmaceutical industry, 2021 compressed
The 10 most eminent leaders in pharmaceutical industry, 2021 compressedThe 10 most eminent leaders in pharmaceutical industry, 2021 compressed
The 10 most eminent leaders in pharmaceutical industry, 2021 compressed
 
J&J Finance Project - new
J&J Finance Project - newJ&J Finance Project - new
J&J Finance Project - new
 
Life Sciences Trends 2014
Life Sciences Trends 2014Life Sciences Trends 2014
Life Sciences Trends 2014
 
Pharma report 2013
Pharma report 2013Pharma report 2013
Pharma report 2013
 
Newtech advant-business-plan9
Newtech advant-business-plan9Newtech advant-business-plan9
Newtech advant-business-plan9
 
Joghnson
JoghnsonJoghnson
Joghnson
 
20071012 ow _beyond_blockbuster
20071012 ow _beyond_blockbuster20071012 ow _beyond_blockbuster
20071012 ow _beyond_blockbuster
 
johnson n johnson
johnson n johnsonjohnson n johnson
johnson n johnson
 
MBA Project
MBA ProjectMBA Project
MBA Project
 
Dendreon Strategic Analysis
Dendreon Strategic AnalysisDendreon Strategic Analysis
Dendreon Strategic Analysis
 
Biotechnology 1
Biotechnology 1Biotechnology 1
Biotechnology 1
 
Johnson & johnson Business Strategy
Johnson & johnson Business StrategyJohnson & johnson Business Strategy
Johnson & johnson Business Strategy
 
Big pharma-uncertain-future
Big pharma-uncertain-futureBig pharma-uncertain-future
Big pharma-uncertain-future
 
johnsonjohnsonbusinessstrategy-140417033017-phpapp02.pdf
johnsonjohnsonbusinessstrategy-140417033017-phpapp02.pdfjohnsonjohnsonbusinessstrategy-140417033017-phpapp02.pdf
johnsonjohnsonbusinessstrategy-140417033017-phpapp02.pdf
 
Gallery Jnj
Gallery JnjGallery Jnj
Gallery Jnj
 
The future of the pharma industry 11.07
The future of the pharma industry 11.07The future of the pharma industry 11.07
The future of the pharma industry 11.07
 
5 Myths of Drug Delivery
5 Myths of Drug Delivery5 Myths of Drug Delivery
5 Myths of Drug Delivery
 
5 Myths of Drug Delivery[1]
5 Myths of Drug Delivery[1]5 Myths of Drug Delivery[1]
5 Myths of Drug Delivery[1]
 
biotech
biotechbiotech
biotech
 

More from homeworkping4

242269855 dell-case-study
242269855 dell-case-study242269855 dell-case-study
242269855 dell-case-studyhomeworkping4
 
242266287 case-study-on-guil
242266287 case-study-on-guil242266287 case-study-on-guil
242266287 case-study-on-guilhomeworkping4
 
242259868 legal-research-cases
242259868 legal-research-cases242259868 legal-research-cases
242259868 legal-research-caseshomeworkping4
 
241999259 case-hemstoma-sukonjungtiva
241999259 case-hemstoma-sukonjungtiva241999259 case-hemstoma-sukonjungtiva
241999259 case-hemstoma-sukonjungtivahomeworkping4
 
241985748 plm-case-study
241985748 plm-case-study241985748 plm-case-study
241985748 plm-case-studyhomeworkping4
 
241946212 case-study-for-ocd
241946212 case-study-for-ocd241946212 case-study-for-ocd
241946212 case-study-for-ocdhomeworkping4
 
241941333 case-digest-statcon
241941333 case-digest-statcon241941333 case-digest-statcon
241941333 case-digest-statconhomeworkping4
 
241909563 impact-of-emergency
241909563 impact-of-emergency241909563 impact-of-emergency
241909563 impact-of-emergencyhomeworkping4
 
241905839 mpcvv-report
241905839 mpcvv-report241905839 mpcvv-report
241905839 mpcvv-reporthomeworkping4
 
241767629 ethics-cases
241767629 ethics-cases241767629 ethics-cases
241767629 ethics-caseshomeworkping4
 
241716493 separation-of-powers-cases
241716493 separation-of-powers-cases241716493 separation-of-powers-cases
241716493 separation-of-powers-caseshomeworkping4
 
241603963 drug-study-final
241603963 drug-study-final241603963 drug-study-final
241603963 drug-study-finalhomeworkping4
 
241573114 persons-cases
241573114 persons-cases241573114 persons-cases
241573114 persons-caseshomeworkping4
 
241566373 workshop-on-case-study
241566373 workshop-on-case-study241566373 workshop-on-case-study
241566373 workshop-on-case-studyhomeworkping4
 
241524597 succession-full-cases
241524597 succession-full-cases241524597 succession-full-cases
241524597 succession-full-caseshomeworkping4
 
241299249 pale-cases-batch-2
241299249 pale-cases-batch-2241299249 pale-cases-batch-2
241299249 pale-cases-batch-2homeworkping4
 
241262134 rubab-thesis
241262134 rubab-thesis241262134 rubab-thesis
241262134 rubab-thesishomeworkping4
 
241259161 citizenship-case-digests
241259161 citizenship-case-digests241259161 citizenship-case-digests
241259161 citizenship-case-digestshomeworkping4
 

More from homeworkping4 (20)

242269855 dell-case-study
242269855 dell-case-study242269855 dell-case-study
242269855 dell-case-study
 
242266287 case-study-on-guil
242266287 case-study-on-guil242266287 case-study-on-guil
242266287 case-study-on-guil
 
242259868 legal-research-cases
242259868 legal-research-cases242259868 legal-research-cases
242259868 legal-research-cases
 
241999259 case-hemstoma-sukonjungtiva
241999259 case-hemstoma-sukonjungtiva241999259 case-hemstoma-sukonjungtiva
241999259 case-hemstoma-sukonjungtiva
 
241985748 plm-case-study
241985748 plm-case-study241985748 plm-case-study
241985748 plm-case-study
 
241946212 case-study-for-ocd
241946212 case-study-for-ocd241946212 case-study-for-ocd
241946212 case-study-for-ocd
 
241941333 case-digest-statcon
241941333 case-digest-statcon241941333 case-digest-statcon
241941333 case-digest-statcon
 
241909563 impact-of-emergency
241909563 impact-of-emergency241909563 impact-of-emergency
241909563 impact-of-emergency
 
241905839 mpcvv-report
241905839 mpcvv-report241905839 mpcvv-report
241905839 mpcvv-report
 
241767629 ethics-cases
241767629 ethics-cases241767629 ethics-cases
241767629 ethics-cases
 
241716493 separation-of-powers-cases
241716493 separation-of-powers-cases241716493 separation-of-powers-cases
241716493 separation-of-powers-cases
 
241603963 drug-study-final
241603963 drug-study-final241603963 drug-study-final
241603963 drug-study-final
 
241585426 cases-vii
241585426 cases-vii241585426 cases-vii
241585426 cases-vii
 
241573114 persons-cases
241573114 persons-cases241573114 persons-cases
241573114 persons-cases
 
241566373 workshop-on-case-study
241566373 workshop-on-case-study241566373 workshop-on-case-study
241566373 workshop-on-case-study
 
241524597 succession-full-cases
241524597 succession-full-cases241524597 succession-full-cases
241524597 succession-full-cases
 
241356684 citibank
241356684 citibank241356684 citibank
241356684 citibank
 
241299249 pale-cases-batch-2
241299249 pale-cases-batch-2241299249 pale-cases-batch-2
241299249 pale-cases-batch-2
 
241262134 rubab-thesis
241262134 rubab-thesis241262134 rubab-thesis
241262134 rubab-thesis
 
241259161 citizenship-case-digests
241259161 citizenship-case-digests241259161 citizenship-case-digests
241259161 citizenship-case-digests
 

Recently uploaded

Meghan Sutherland In Media Res Media Component
Meghan Sutherland In Media Res Media ComponentMeghan Sutherland In Media Res Media Component
Meghan Sutherland In Media Res Media ComponentInMediaRes1
 
Pharmacognosy Flower 3. Compositae 2023.pdf
Pharmacognosy Flower 3. Compositae 2023.pdfPharmacognosy Flower 3. Compositae 2023.pdf
Pharmacognosy Flower 3. Compositae 2023.pdfMahmoud M. Sallam
 
Presiding Officer Training module 2024 lok sabha elections
Presiding Officer Training module 2024 lok sabha electionsPresiding Officer Training module 2024 lok sabha elections
Presiding Officer Training module 2024 lok sabha electionsanshu789521
 
MARGINALIZATION (Different learners in Marginalized Group
MARGINALIZATION (Different learners in Marginalized GroupMARGINALIZATION (Different learners in Marginalized Group
MARGINALIZATION (Different learners in Marginalized GroupJonathanParaisoCruz
 
Employee wellbeing at the workplace.pptx
Employee wellbeing at the workplace.pptxEmployee wellbeing at the workplace.pptx
Employee wellbeing at the workplace.pptxNirmalaLoungPoorunde1
 
Difference Between Search & Browse Methods in Odoo 17
Difference Between Search & Browse Methods in Odoo 17Difference Between Search & Browse Methods in Odoo 17
Difference Between Search & Browse Methods in Odoo 17Celine George
 
What is Model Inheritance in Odoo 17 ERP
What is Model Inheritance in Odoo 17 ERPWhat is Model Inheritance in Odoo 17 ERP
What is Model Inheritance in Odoo 17 ERPCeline George
 
Types of Journalistic Writing Grade 8.pptx
Types of Journalistic Writing Grade 8.pptxTypes of Journalistic Writing Grade 8.pptx
Types of Journalistic Writing Grade 8.pptxEyham Joco
 
ECONOMIC CONTEXT - LONG FORM TV DRAMA - PPT
ECONOMIC CONTEXT - LONG FORM TV DRAMA - PPTECONOMIC CONTEXT - LONG FORM TV DRAMA - PPT
ECONOMIC CONTEXT - LONG FORM TV DRAMA - PPTiammrhaywood
 
Gas measurement O2,Co2,& ph) 04/2024.pptx
Gas measurement O2,Co2,& ph) 04/2024.pptxGas measurement O2,Co2,& ph) 04/2024.pptx
Gas measurement O2,Co2,& ph) 04/2024.pptxDr.Ibrahim Hassaan
 
AmericanHighSchoolsprezentacijaoskolama.
AmericanHighSchoolsprezentacijaoskolama.AmericanHighSchoolsprezentacijaoskolama.
AmericanHighSchoolsprezentacijaoskolama.arsicmarija21
 
Framing an Appropriate Research Question 6b9b26d93da94caf993c038d9efcdedb.pdf
Framing an Appropriate Research Question 6b9b26d93da94caf993c038d9efcdedb.pdfFraming an Appropriate Research Question 6b9b26d93da94caf993c038d9efcdedb.pdf
Framing an Appropriate Research Question 6b9b26d93da94caf993c038d9efcdedb.pdfUjwalaBharambe
 
DATA STRUCTURE AND ALGORITHM for beginners
DATA STRUCTURE AND ALGORITHM for beginnersDATA STRUCTURE AND ALGORITHM for beginners
DATA STRUCTURE AND ALGORITHM for beginnersSabitha Banu
 
Alper Gobel In Media Res Media Component
Alper Gobel In Media Res Media ComponentAlper Gobel In Media Res Media Component
Alper Gobel In Media Res Media ComponentInMediaRes1
 
Proudly South Africa powerpoint Thorisha.pptx
Proudly South Africa powerpoint Thorisha.pptxProudly South Africa powerpoint Thorisha.pptx
Proudly South Africa powerpoint Thorisha.pptxthorishapillay1
 
Introduction to ArtificiaI Intelligence in Higher Education
Introduction to ArtificiaI Intelligence in Higher EducationIntroduction to ArtificiaI Intelligence in Higher Education
Introduction to ArtificiaI Intelligence in Higher Educationpboyjonauth
 
Final demo Grade 9 for demo Plan dessert.pptx
Final demo Grade 9 for demo Plan dessert.pptxFinal demo Grade 9 for demo Plan dessert.pptx
Final demo Grade 9 for demo Plan dessert.pptxAvyJaneVismanos
 
Enzyme, Pharmaceutical Aids, Miscellaneous Last Part of Chapter no 5th.pdf
Enzyme, Pharmaceutical Aids, Miscellaneous Last Part of Chapter no 5th.pdfEnzyme, Pharmaceutical Aids, Miscellaneous Last Part of Chapter no 5th.pdf
Enzyme, Pharmaceutical Aids, Miscellaneous Last Part of Chapter no 5th.pdfSumit Tiwari
 

Recently uploaded (20)

Meghan Sutherland In Media Res Media Component
Meghan Sutherland In Media Res Media ComponentMeghan Sutherland In Media Res Media Component
Meghan Sutherland In Media Res Media Component
 
TataKelola dan KamSiber Kecerdasan Buatan v022.pdf
TataKelola dan KamSiber Kecerdasan Buatan v022.pdfTataKelola dan KamSiber Kecerdasan Buatan v022.pdf
TataKelola dan KamSiber Kecerdasan Buatan v022.pdf
 
Pharmacognosy Flower 3. Compositae 2023.pdf
Pharmacognosy Flower 3. Compositae 2023.pdfPharmacognosy Flower 3. Compositae 2023.pdf
Pharmacognosy Flower 3. Compositae 2023.pdf
 
Presiding Officer Training module 2024 lok sabha elections
Presiding Officer Training module 2024 lok sabha electionsPresiding Officer Training module 2024 lok sabha elections
Presiding Officer Training module 2024 lok sabha elections
 
OS-operating systems- ch04 (Threads) ...
OS-operating systems- ch04 (Threads) ...OS-operating systems- ch04 (Threads) ...
OS-operating systems- ch04 (Threads) ...
 
MARGINALIZATION (Different learners in Marginalized Group
MARGINALIZATION (Different learners in Marginalized GroupMARGINALIZATION (Different learners in Marginalized Group
MARGINALIZATION (Different learners in Marginalized Group
 
Employee wellbeing at the workplace.pptx
Employee wellbeing at the workplace.pptxEmployee wellbeing at the workplace.pptx
Employee wellbeing at the workplace.pptx
 
Difference Between Search & Browse Methods in Odoo 17
Difference Between Search & Browse Methods in Odoo 17Difference Between Search & Browse Methods in Odoo 17
Difference Between Search & Browse Methods in Odoo 17
 
What is Model Inheritance in Odoo 17 ERP
What is Model Inheritance in Odoo 17 ERPWhat is Model Inheritance in Odoo 17 ERP
What is Model Inheritance in Odoo 17 ERP
 
Types of Journalistic Writing Grade 8.pptx
Types of Journalistic Writing Grade 8.pptxTypes of Journalistic Writing Grade 8.pptx
Types of Journalistic Writing Grade 8.pptx
 
ECONOMIC CONTEXT - LONG FORM TV DRAMA - PPT
ECONOMIC CONTEXT - LONG FORM TV DRAMA - PPTECONOMIC CONTEXT - LONG FORM TV DRAMA - PPT
ECONOMIC CONTEXT - LONG FORM TV DRAMA - PPT
 
Gas measurement O2,Co2,& ph) 04/2024.pptx
Gas measurement O2,Co2,& ph) 04/2024.pptxGas measurement O2,Co2,& ph) 04/2024.pptx
Gas measurement O2,Co2,& ph) 04/2024.pptx
 
AmericanHighSchoolsprezentacijaoskolama.
AmericanHighSchoolsprezentacijaoskolama.AmericanHighSchoolsprezentacijaoskolama.
AmericanHighSchoolsprezentacijaoskolama.
 
Framing an Appropriate Research Question 6b9b26d93da94caf993c038d9efcdedb.pdf
Framing an Appropriate Research Question 6b9b26d93da94caf993c038d9efcdedb.pdfFraming an Appropriate Research Question 6b9b26d93da94caf993c038d9efcdedb.pdf
Framing an Appropriate Research Question 6b9b26d93da94caf993c038d9efcdedb.pdf
 
DATA STRUCTURE AND ALGORITHM for beginners
DATA STRUCTURE AND ALGORITHM for beginnersDATA STRUCTURE AND ALGORITHM for beginners
DATA STRUCTURE AND ALGORITHM for beginners
 
Alper Gobel In Media Res Media Component
Alper Gobel In Media Res Media ComponentAlper Gobel In Media Res Media Component
Alper Gobel In Media Res Media Component
 
Proudly South Africa powerpoint Thorisha.pptx
Proudly South Africa powerpoint Thorisha.pptxProudly South Africa powerpoint Thorisha.pptx
Proudly South Africa powerpoint Thorisha.pptx
 
Introduction to ArtificiaI Intelligence in Higher Education
Introduction to ArtificiaI Intelligence in Higher EducationIntroduction to ArtificiaI Intelligence in Higher Education
Introduction to ArtificiaI Intelligence in Higher Education
 
Final demo Grade 9 for demo Plan dessert.pptx
Final demo Grade 9 for demo Plan dessert.pptxFinal demo Grade 9 for demo Plan dessert.pptx
Final demo Grade 9 for demo Plan dessert.pptx
 
Enzyme, Pharmaceutical Aids, Miscellaneous Last Part of Chapter no 5th.pdf
Enzyme, Pharmaceutical Aids, Miscellaneous Last Part of Chapter no 5th.pdfEnzyme, Pharmaceutical Aids, Miscellaneous Last Part of Chapter no 5th.pdf
Enzyme, Pharmaceutical Aids, Miscellaneous Last Part of Chapter no 5th.pdf
 

Johnson & Johnson's Success Through Innovation and Collaboration

  • 1. Homework Help https://www.homeworkping.com/ Research Paper help https://www.homeworkping.com/ Online Tutoring https://www.homeworkping.com/ UKRIDA MAGISTER MANAGEMENT PROGRAM PERIODE 2010 Class: Creative Marketing By Prof Dr… Analysis on the Case 2-4 Johnson & Johnson Prepared By: 1. Darwin Lesmana NIM : 01-2010-12 2. ….
  • 2. 3. …. 4. … 5. … 6. … 7. …
  • 3. 1. Introduction:  Johnson & Johnson (“J&J”) is one of the largest enterprises in the world. The Company has established for 117 years, made up with 204 different businesses organized into three divisions: a. Drugs (Pharmaceutical) b. Medical Devices & Diagnostic c. Consumer Products.  The Pharmaceutical division is the major contributor to the Company’s Growth, they accounted for almost half of the Company’s Sales and contribute 61% of the previous year operating profit. The consumer products Band Aid and Baby Powder is also well known to consumer.  The Company also well known for the development of Innovative Products, aggressive selling, favorable prices and an unusual move of advertisement, example: - In 1991, they launch Procrit (for treating Anemia in Chemotheraphy) where J&J spend millions to educate physician and also advertisement on TV. This is an unusual common practice for Cancer Drug to be advertised on TV, however they succeed with the proven that Procrit is now the best selling drug of J&J.  J&J is famed for giving for delivering at least 10% earnings growth year in and year out going back nearly two decades. In the first quarter, it reported 13% rise. The Stock Price has increased from less than $ 3 in the mid 1980 to almost 20 times that now. Although the Standard and Poors 500 Stock index has fallen 28,1% but J&J stock increased 19,4%. In 2002, J&J earned $ 6,8 billion compared with $ 5.9 billion the previous year (15% growth)  J&J is fulfilled with great employees, however one of the great employees was William C Weldons, who was onetime a drug salesman and now becoming the leader of the Health Care Division. He is famed for the ability to convince, cajole and sometimes just sweet talk colleagues into seeing things his way. One of the most succesful story of Weldons ability in convincing people was when he succeeded in persuading the Chief Pharmaceutical “ Dr Per A Peterson” to stay for J&J, although the Doctor has decide for leaving the Company. 2. Important Highlights
  • 4.  Maintaining the growth records to keep sustainably increase was one of the Company’s problems. To keep up, the Company must make a new $ 4 billion business every year. Meanwhile there were some difficulties which the Company’s facing such as: - Procrit sales were nearly flat in the 1st quarter due to the new rival, and the news has impacting on the Company’s stock which decrease 3% in one day. - Although the new drug coated stent has been held up at the Food and Drug Administration and approval seems highly likely but if the devices does not get the OK , it would be one big problem for J&J.  J&J style in acquisitions to continue growing has also created another problem. The Company has bought 52 business for over $ 30 billion over the past decade, 10-15% of top line growth was due to investment. Finding and acquisition that is fit with the Company’s business and make contribution becomes increasingy difficult.  J&J is one big Company with many subsidiaries, where each of the subsidiaries run their own Company independently. Each of the Subsidiaries set their own strategies, their own finance and human resources departments. This is creating a relatively high overhead cost.  Weldons as one the leader in J&J has believe that the important breakthrough in the 21st Century medicine is the ability to apply scientific advances in one discipline to another, such as: - Sutures are coated with drugs to prevent infections. - Defibrillators may be linked to computer that alerts doctors when patient have abnormal heart diseases. The Company should combine between Drugs, Devices & Diagnostic. By implementing that, it has boost the Development and Research Budget by more than 10%, and it has employed 9.300 scientist in 40 labs around the world.  In order to achieve the 21st Century breakthrough, J&J’s independent business unit (Subsidiaries) must work together. Therefore Weldon has created a new system to foster better communication and more frequent collaboration among J&J disparate operations.  J&J has been inching to that with the new drugs coated stent which could revolutionize the field of cardiology. It has grew out of a discussion in the mid 90’s between Drug researcher and one in J&J stent business. This kind of
  • 5. example is what the Company’s need in order to make the independent business unit (Subsidiaries) work together.  Inline the breakthrough, Weldons personifies the Company’s Ethos such as: - Although becoming the first Executives to go casual in 1990, but he is a compulsively competitive. One of the famous quotation was: “ It’s not fun to be second”. - Weldon was also became famous for setting near impossible goals for his people. - His is turning up the Company’s with the cooperation between his different units to have meeting quarterly for the past five years to share information. - Creating new breakthrough such as creating committee comprised of R&D executives and senior managers instead of scientist for some fixing some failure.  Although the breakthrough by Weldon wont yield results for years, however there was some evidence that the new collaboration is working, such as: - J&J Pharmaceutical operation working the Companys’ drug delivery operation Alza. - New diagnostic unit is working with data generated by drug researcher. - In 2002, J&J rolled out the new Band Aid Brand, which formerly used by hospital, now sold through the public. - Changes in prescription antifungal treatment Nizoral into a dandruff Shampoo. These changes has increase the Operating Margins for the Consumer Business from 13,8% in 2000 to 18,7% in 2002.  Facts about Weldon: - Weldon spent much of his time on the road travelling to meet surgeons and hospital executives. - Weldon often set more ambitious goals than the headquarters. - He doesn’t like to be disappointed. - He is an intimidator and a dominator - Weldon’s background was not from a wealthy educated family. His father was a stagehand on Broadway, while his mother was a seamstress worked for the ballet and theater costumes. - Weldon was grew up in one of the less prosperous neighborhood. - While in college, he has begin to work as a mover on the weekends and public holidays.
  • 6. - He’s first and only interview for work as at J&J and started his career as a salesman at the Mc Neil Pharmaceutical units.  At this point, most of J&J’s important drugs as under threat from competitors, such as: - Procrit (Company’s biggest selling product) has been threat by Aranesp (product from Amgen Inc) and also side problem from European version called Eprex which resulting Procrit sales may actually decline 2% in 2003. - $1.3 billions Rheumatoid Arthritis drug Remicade faces competing products from Amgen and Abbott Labs.  With the J&J blockbusters slowing, Weldon expect his successor to do something dramatic, like what he did two years ago when he completed J&J biggest acquisition ever by buying the drug delivery player Alza corp for $13.2 Billion. Reason for the acquisition was Alza’s Technology could help J&J devise safer and more effective formulations of exisiting drugs. But buying growth would be difficult these days. Nearly every pharmaceutical company is looking for deal with J&J, but finding the right one would be a difficult problems.  Now the drugs business is taken care by the new boss Christine A Poon who was recruited by Waldens from Bristol Myers Squibb Co. But Weldons still jumps in every now and then. Such as when the Senior Executives was hammering out details of $ 2.4 Billions acquisitions of Scios Inc, Walden came and supporting Poons, due to it was her first acquisitions. But Waldons also have to be carefull not to cross the line between supporting his executives and encroaching on their territory. 3. Implication to the Market Driven Strategies: a. Becoming Market- Orientation J&J has become the Market Orientation which can be proven by the facts about: - They keep on focusing on their core business in Drug, Medicine Devices and Consumer Products and keep on continuing on research for what the market demands and creating innovative products. Example new drug coated stent called Cypher. Stent is used to prop open arteries after angioplasty, Cypher is coated with a drug that prevents those arteries from re-clogging. - Almost all consumer known the products of Band Aid and Baby powder which quality was consistently control, showing that J&J brands has been the market orientation.
  • 7. b. Determining Distinctive Capabilities Distinctive Capabilities that J&J have was: - J&J have one of the Best Human Resources Assets which was Mr William C Weldon who has super brilliant ideas which changes the ethos of J&J work attitude, by creating an cooperation between Drugs, Medical Services and Diagnostics. - With the Company’s wealth over 2 decades of 10% sustain growth, they have precious assets in developing new products with employing over 9.300 scientist in 40 labs around the world. - Also inline with the Company’s wealth, they have the potential money in acquisition of some company’s which core business will support the development of J&J, such as the purchased of Technology Company Alza. c. Customers Value/Capabilities Match Creating value for customers: - Hospital purchase products from J&J due to the favourable prices that J&J given for the whole package, giving the best product with the best price to the customers. - The Producs Cypher giving value to the Stent with coating it with drugs which prevents those arteries from reclogging, which was giving value to the patients. - The Company’s sustainable growth which made the stock growth almost 20 times from less than $ 3, which giving values and benefit for the stockholders. d. Achieving Superior Performance J&J has achieve Superior Performance such as: - In the first quarter, it reported 13% rise. The Stock Price has increased from less than $ 3 in the mid 1980 to almost 20 times that now. Although the Standard and Poors 500 Stock index has fallen 28,1% but J&J stock increased 19,4%. In 2002, J&J earned $ 6,8 billion compared with $ 5.9 billion the previous year (15% growth). However although it has achieve the superior performance, there were some obstacle: - Maintaining the growth records to keep sustainably increase was one of the Company’s problems. To keep up, the Company must make a new $ 4 billion business every year. - Finding and acquisition that is fit with the Company’s business and make contribution becomes increasingy difficult. - J&J is one big Company with many subsidiaries, where each of the subsidiaries run their own Company independently. Each of the Subsidiaries set their own strategies, their own finance and human resources departments. This is creating a relatively high overhead cost.
  • 8. 4. Conclusion: In order for the Companys to keep continuing: a. In order to achieve the 21st Century breakthrough, J&J’s independent business unit (Subsidiaries) must work together. This program must work in order to makes more innovative products. b. With the collaboration, they should make some merger of some company’s in order to reduce the High Cost of Overhead, Finance and Human Resources Department. c. Be More selective and more prudent in acquisition, must ensure that the acquisition is really2 inline with the Company’s core business. Homework Help https://www.homeworkping.com/ Math homework help https://www.homeworkping.com/ Research Paper help https://www.homeworkping.com/ Algebra Help https://www.homeworkping.com/ Calculus Help https://www.homeworkping.com/ Accounting help
  • 9. https://www.homeworkping.com/ Paper Help https://www.homeworkping.com/ Writing Help https://www.homeworkping.com/ Online Tutor https://www.homeworkping.com/ Online Tutoring https://www.homeworkping.com/